Results 71 to 80 of about 21,018 (198)

Bioorthogonal Chemistry in Biomolecule Quantification: A Review of Reactions and Strategies

Chemistry – A European Journal, Volume 32, Issue 1, 2 January 2026.
This review summarizes the application of catalyst‐free bioorthogonal reactions: Staudinger ligation, strain promoted azide alkyne cycloaddition, inverse electron‐demand Diels–Alder, and 2‐cyanobenzothiazole cysteine condensation in the semi‐quantitative and quantitative analysis of biomolecules.
Mingze Yang, Shiqi Wang
wiley   +1 more source

Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) [PDF]

, 2023
Catherine Thiéblemont, Kunlun Wang, Sam Keeping, Isabella Zhang, Kai Yang, Bixia Tang, Leyla Mohseninejad   +6 more
openalex   +1 more source

Targeting the TRIM28–EZH2 Protein–Protein Interface With Cysteine‐Reactive Covalent Inhibitors: A Computational Blueprint for Cancer Therapy

Chemistry &Biodiversity, Volume 23, Issue 1, January 2026.
Graphical overview of the computational strategy employed to disrupt the oncogenic TRIM28EZH2 proteinprotein interaction. The workflow illustrates proteinprotein docking to define the interaction interface, cysteine‐focused covalent virtual screening targeting EZH2 Cys144, covalent docking, molecular dynamics simulations, and MM‐GBSA binding free ...
Ibrahim Oluwatobi Kehinde, Vuyisa Mzozoyana, Sizwe J. Zamisa, Mbuso Faya, Mahmoud E. S. Soliman   +4 more
wiley   +1 more source

Electrocardiographic Changes Associated With Ibrutinib Exposure

Cancer Control, 2020
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib’s effects on other electrocardiographic parameters, particularly the QT interval.
Michael G. Fradley MD, Allan Welter-Frost MD, Matthew Gliksman BS, Josephine Emole MD, Federico Viganego MD, Dae Hyun Lee MD, Bijal Shah MD, Julio C. Chavez MD, Javier Pinilla-Ibarz MD, PhD, Matthew B. Schabath PhD   +9 more
doaj   +1 more source

Phagocytosis of Lymphocytes and Erythrocytes by B‐Cell Lymphoma in a Patient With a Clinical Suspicion of Pure Red Cell Aplasia

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Herein, we report a diagnostically challenging case of a B‐cell lymphoma initially masquerading as pure red cell aplasia (PRCA). The key to diagnosis was the unique finding of phagocytic activity (engulfing erythrocytes and lymphocytes) by atypical mature lymphocytes in both peripheral blood and bone marrow, accompanied by clinical signs of ...
Tuo Cao, Yuting Li, Xiangming Peng
wiley   +1 more source

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial [PDF]

, 2022
G.A. Amos Burke, Luciana Vinti, Edita Kabíčková, Auke Beishuizen, Nurdan Taçyıldız, Anne Uyttebroeck, Hyoung Jin Kang, Flávio Augusto Vercillo Luisi, Véronique Minard‐Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin E. Norris, Mitchell S. Cairo   +19 more
openalex   +1 more source

Extranodal Lymphoplasmacytic Lymphoma Responding Rapidly to Zanubrutinib: A Case Series

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Management of recurrent or atypical lymphoplasmacytic lymphoma poses a significant therapeutic challenge. Here we demonstrate a case series of three patients with atypical presentations of extranodal lymphoplasmacytic lymphoma that each show remarkable and timely responses to Zanubrutinib with a limited side effect profile.
Samuel Brown, Jillian Rusbridge, George Follows, Anna Santarsieri   +3 more
wiley   +1 more source

Mitigating Ibrutinib‐Induced Ventricular Arrhythmia and Cardiac Dysfunction With Metformin

Cancer Innovation
Background Ibrutinib is a first‐line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use.
Pengsha Li, Daiqi Liu, Pan Gao, Ming Yuan, Zhiqiang Zhao, Yue Zhang, Zandong Zhou, Qingling Zhang, Meng Yuan, Xing Liu, Gary Tse, Guangping Li, Qiankun Bao, Tong Liu   +13 more
doaj   +1 more source

ALK‐Positive Histiocytosis With Unilateral Breast Involvement: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT APH is a rare disorder characterized by the proliferation of ALK‐expressing histiocytes with variable anatomical involvement; however, mammary involvement is exceptionally rare. A 32‐year‐old woman presented with a painless right breast mass. Ultrasound identified a 9 × 8 mm hypoechoic nodule, categorized as BI‐RADS 4A.
Xuechun Liu, Dong Ren, Yanfang Liang
wiley   +1 more source

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Haematologica, 2018
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy.
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D. Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H. Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D. Nasta, Spencer H. Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S. Ujjani   +25 more
doaj   +1 more source